{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:53:48Z","timestamp":1781654028503,"version":"3.54.5"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82101893"],"award-info":[{"award-number":["82101893"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Science and Technology Innovation Project of Applied Basic Research (Medical and Health) of Suzhou","award":["SYW2025050"],"award-info":[{"award-number":["SYW2025050"]}]},{"name":"Suzhou Municipal Hospital's Special Fund for \"Promoting Health through Science and Education\"","award":["Szslyyrc202502005"],"award-info":[{"award-number":["Szslyyrc202502005"]}]},{"name":"The First Affiliated Hospital of Soochow University BOXI Clinical Research Project","award":["BXLC016"],"award-info":[{"award-number":["BXLC016"]}]},{"name":"Research Project of China Medical Education Association","award":["HJ-RD-2024-34"],"award-info":[{"award-number":["HJ-RD-2024-34"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-026-04228-1","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:12:24Z","timestamp":1777479144000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dual-mechanism inhalable nanocomposite restores the alveolar mucus barrier and enables deep-lesion delivery for synergistic treatment of pulmonary fibrosis"],"prefix":"10.1186","volume":"24","author":[{"given":"Zhiliang","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengting","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weicheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dachuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianlong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caihong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianming","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"4228_CR1","doi-asserted-by":"publisher","first-page":"e066354","DOI":"10.1136\/bmj-2021-066354","volume":"377","author":"GY Liu","year":"2022","unstructured":"Liu GY, Budinger GRS, Dematte JE. Advances in the management of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. BMJ. 2022;377:e066354. https:\/\/doi.org\/10.1136\/bmj-2021-066354","journal-title":"BMJ"},{"key":"4228_CR2","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1146\/annurev-pathol-042320-030240","volume":"17","author":"BJ Moss","year":"2022","unstructured":"Moss BJ, Ryter SW, Rosas IO. Pathogenic mechanisms underlying idiopathic pulmonary fibrosis. Annu Rev Pathol. 2022;17:515\u2013 546. https:\/\/doi.org\/10.1146\/annurev-pathol-042320-030240","journal-title":"Annu Rev Pathol"},{"key":"4228_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.115051","volume":"200","author":"H Han","year":"2023","unstructured":"Han H, Xing L, Chen BT, Liu Y, Zhou TJ, Wang Y, et al. Progress on the pathological tissue microenvironment barrier-modulated nanomedicine. Adv Drug Deliv Rev. 2023;200:115051. https:\/\/doi.org\/10.1016\/j.addr.2023.115051.","journal-title":"Adv Drug Deliv Rev"},{"issue":"10","key":"4228_CR4","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1002\/mco2.744","volume":"5","author":"J Wang","year":"2020","unstructured":"Wang J, Li K, Hao D, Li X, Zhu Y, Yu H, Chen H. Pulmonary fibrosis: pathogenesis and therapeutic strategies. MedComm. 2020;5(10):2024\u2013e744. https:\/\/doi.org\/10.1002\/mco2.744.","journal-title":"MedComm"},{"issue":"11","key":"4228_CR5","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/nrd.2017.170","volume":"16","author":"AL Mora","year":"2017","unstructured":"Mora AL, Rojas M, Pardo A, Selman M. Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease. Nat Rev Drug Discov. 2017;16(11):755\u2013772.https:\/\/doi.org\/10.1038\/nrd.2017.170","journal-title":"Nat Rev Drug Discov"},{"issue":"17","key":"4228_CR6","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1007\/s40265-023-01950-0","volume":"83","author":"F Bonella","year":"2023","unstructured":"Bonella F, Spagnolo P, Ryerson C. Current and future treatment landscape for idiopathic pulmonary fibrosis. Drugs. 2023;83(17):1581\u20131593. https:\/\/doi.org\/10.1007\/s40265-023-01950-0.","journal-title":"Drugs"},{"key":"4228_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116282","volume":"173","author":"J Ma","year":"2024","unstructured":"Ma J, Li G, Wang H, Mo C. Comprehensive review of potential drugs with anti-pulmonary fibrosis properties. Biomed Pharmacother. 2024;173:116282.https:\/\/doi.org\/10.1016\/j.biopha.2024.116282","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"4228_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00834-8","volume":"8","author":"L Guo","year":"2017","unstructured":"Guo L, Luo S, Du Z, Zhou M, Li P, Fu Y, et al. Targeted delivery of celastrol to mesangial cells is effective against mesangioproliferative glomerulonephritis. Nat Commun. 2017;8(1):878. https:\/\/doi.org\/10.1038\/s41467-017-00834-8.","journal-title":"Nat Commun"},{"key":"4228_CR9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jconrel.2020.01.017","volume":"320","author":"R Li","year":"2020","unstructured":"Li R, Li Y, Zhang J, Liu Q, Wu T, Zhou J, Huang H, Tang Q, Huang C, Huang Y, Zhang Z, Zhang G, Zhao Y, Ma L, Feng Y, Mo L, Han M, He J. Targeted delivery of celastrol to renal interstitial myofibroblasts using fibronectin-binding liposomes attenuates renal fibrosis and reduces systemic toxicity. J Control Release. 2020;320:32\u201344.https:\/\/doi.org\/10.1016\/j.jconrel.2020.01.017","journal-title":"J Control Release"},{"key":"4228_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2019.153160","volume":"67","author":"X Jiang","year":"2020","unstructured":"Jiang X, Chen S, Zhang Q, Yi C, He J, Ye X, et al. Celastrol is a novel selective agonist of cannabinoid receptor 2 with anti-inflammatory and anti-fibrotic activity in a mouse model of systemic sclerosis. Phytomedicine. 2020;67:153160. https:\/\/doi.org\/10.1016\/j.phymed.2019.153160.","journal-title":"Phytomedicine"},{"key":"4228_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105572","volume":"167","author":"S Xu","year":"2021","unstructured":"Xu S, Feng Y, He W, Xu W, Xu W, Yang H, et al. Celastrol in metabolic diseases: progress and application prospects. Pharmacol Res. 2021;167:105572. https:\/\/doi.org\/10.1016\/j.phrs.2021.105572","journal-title":"Pharmacol Res"},{"key":"4228_CR12","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.freeradbiomed.2024.12.017","volume":"227","author":"X Deng","year":"2025","unstructured":"Deng X, He J, Deng W, Deng W, Zhu X, Luo H, Wang D. Celastrol ameliorates lipopolysaccharide (LPS)-induced acute lung injury by improving mitochondrial function through AMPK\/PGC-1alpha\/Nrf1-dependent mechanism. Free Radic Biol Med. 2025;227:210\u201320. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2024.12.017.","journal-title":"Free Radic Biol Med"},{"issue":"10","key":"4228_CR13","doi-asserted-by":"publisher","first-page":"4549","DOI":"10.1002\/ptr.70077","volume":"39","author":"B Wang","year":"2025","unstructured":"Wang B, Xu T, Yu L, Qiu C, Xu J, Zhao X, et al. Celastrol suppresses SHH-MB growth via ROS-induced stress: evidence from in vitro and in vivo studies. Phytother Res. 2025;39(10):4549\u20134565. https:\/\/doi.org\/10.1002\/ptr.70077.","journal-title":"Phytother Res"},{"issue":"9","key":"4228_CR14","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1136\/ard-2023-223859","volume":"82","author":"P Chitturi","year":"2023","unstructured":"Chitturi P, Xu S, Ahmed Abdi B, Nguyen J, Carter DE, Sinha S, et al. Tripterygium wilfordii derivative celastrol, a YAP inhibitor, has antifibrotic effects in systemic sclerosis. Ann Rheum Dis. 2023;82(9):1191\u20131204. https:\/\/doi.org\/10.1136\/ard-2023-223859.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4228_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0666-y","volume":"9","author":"M Tang","year":"2018","unstructured":"Tang M, Cao X, Zhang K, Li Y, Zheng QY, Li GQ, et al. Celastrol alleviates renal fibrosis by upregulating cannabinoid receptor 2 expression. Cell Death Dis. 2018;9(6):601. https:\/\/doi.org\/10.1038\/s41419-018-0666-y","journal-title":"Cell Death Dis"},{"issue":"Pt 5","key":"4228_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.137289","volume":"282","author":"T Zheng","year":"2024","unstructured":"Zheng T, Gan X, Luo J, Shi Z, Zhao Y, Wang Y, et al. Hyaluronic acid act as drug self-assembly chaperone and co-assembled with celalstrol for ameliorating non-alcoholic steatohepatitis. Int J Biol Macromol. 2024;282(Pt 5):137289. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.137289.","journal-title":"Int J Biol Macromol"},{"key":"4228_CR17","doi-asserted-by":"publisher","first-page":"10907","DOI":"10.2147\/IJN.S539586","volume":"20","author":"P He","year":"2025","unstructured":"He P, Sun J, Tan J, Shi YN, Zhang CJ, Zhu N, et al. From physicochemical constraints to clinical prospects of Celastrol: challenges and nano delivery strategies. Int J Nanomedicine. 2025;20:10907\u201310931. https:\/\/doi.org\/10.2147\/IJN.S539586.","journal-title":"Int J Nanomedicine"},{"key":"4228_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/nu12041131","author":"P Faverio","year":"2020","unstructured":"Faverio P, Bocchino M, Caminati A, Fumagalli A, Gasbarra M, Iovino P, et al. Nutrition in patients with idiopathic pulmonary fibrosis: critical issues analysis and future research directions. Nutrients. 2020. https:\/\/doi.org\/10.3390\/nu12041131.","journal-title":"Nutrients"},{"issue":"10","key":"4228_CR19","doi-asserted-by":"publisher","first-page":"e26634","DOI":"10.1371\/journal.pone.0026634","volume":"6","author":"J Hansen","year":"2011","unstructured":"Hansen J, Palmfeldt J, Vang S, Corydon TJ, Gregersen N, Bross P. Quantitative proteomics reveals cellular targets of celastrol. PLoS One. 2011;6(10):e26634. https:\/\/doi.org\/10.1371\/journal.pone.0026634.","journal-title":"PLoS One"},{"key":"4228_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ph17060709","author":"M Chianese","year":"2024","unstructured":"Chianese M, Screm G, Salton F, Confalonieri P, Trotta L, Barbieri M, et al. Pirfenidone and nintedanib in pulmonary fibrosis: lights and shadows. Pharmaceuticals (Basel). 2024. https:\/\/doi.org\/10.3390\/ph17060709.","journal-title":"Pharmaceuticals (Basel)"},{"key":"4228_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.178159","volume":"1006","author":"P Sharma","year":"2025","unstructured":"Sharma P, Kumari K, Yadav R, Verma K, Paliwal S, Paliwal S, et al. Molecular mechanisms and emerging therapeutics in pulmonary fibrosis: a recent update. Eur J Pharmacol. 2025;1006:178159.https:\/\/doi.org\/10.1016\/j.ejphar.2025.178159","journal-title":"Eur J Pharmacol"},{"key":"4228_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.115144","volume":"203","author":"M Zhang","year":"2023","unstructured":"Zhang M, Lu H, Xie L, Liu X, Cun D, Yang M. Inhaled RNA drugs to treat lung diseases: disease-related cells and nano-bio interactions. Adv Drug Deliv Rev. 2023;203:115144. https:\/\/doi.org\/10.1016\/j.addr.2023.115144.","journal-title":"Adv Drug Deliv Rev"},{"key":"4228_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2024.100966","volume":"25","author":"B Wang","year":"2024","unstructured":"Wang B, Wang L, Yang Q, Zhang Y, Qinglai T, Yang X, et al. Pulmonary inhalation for disease treatment: basic research and clinical translations. Mater Today Bio. 2024;25:100966. https:\/\/doi.org\/10.1016\/j.mtbio.2024.100966.","journal-title":"Mater Today Bio"},{"issue":"1","key":"4228_CR24","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1124\/pharmrev.120.000108","volume":"74","author":"S Anderson","year":"2022","unstructured":"Anderson S, Atkins P, Backman P, Cipolla D, Clark A, Daviskas E, et al. Inhaled medicines: past, present, and future. Pharmacol Rev. 2022;74(1):48\u2013118. https:\/\/doi.org\/10.1124\/pharmrev.120.000108.","journal-title":"Pharmacol Rev"},{"issue":"9","key":"4228_CR25","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1136\/thorax-2022-219391","volume":"78","author":"A West","year":"2023","unstructured":"West A, Chaudhuri N, Barczyk A, Wilsher ML, Hopkins P, Glaspole I, Corte TJ, Sterclova M, Veale A, Jassem E, Wijsenbeek MS, Grainge C, Piotrowski W, Raghu G, Shaffer ML, Nair D, Freeman L, Otto K, Montgomery AB. Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose-response trial. Thorax. 2023;78(9):882\u2013889. https:\/\/doi.org\/10.1136\/thorax-2022-219391","journal-title":"Thorax"},{"key":"4228_CR26","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.jconrel.2020.07.011","volume":"326","author":"AM Shen","year":"2020","unstructured":"Shen AM, Minko T. Pharmacokinetics of inhaled nanotherapeutics for pulmonary delivery. J Control Release. 2020;326:222\u2013244. https:\/\/doi.org\/10.1016\/j.jconrel.2020.07.011.","journal-title":"J Control Release"},{"key":"4228_CR27","doi-asserted-by":"publisher","unstructured":"Zhang SW, Edwards DA, Langer R, Cheng K. Inhalable materials and biologics for lung defence and drug delivery. Nat Rev Mater . 2026;11:90-116. https:\/\/doi.org\/10.1038\/s41578-025-00841-y","DOI":"10.1038\/s41578-025-00841-y"},{"issue":"1","key":"4228_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-022-01307-x","volume":"20","author":"S He","year":"2022","unstructured":"He S, Gui J, Xiong K, Chen M, Gao H, Fu Y. A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases. J Nanobiotechnology. 2022;20(1):101. https:\/\/doi.org\/10.1186\/s12951-022-01307-x.","journal-title":"J Nanobiotechnology"},{"key":"4228_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2025.102778","author":"JY Lu","year":"2025","unstructured":"Lu JY, Sun L, Mei D, Liu C, Xia T, Li JL, et al. Engineering inhalable nanomedicines to navigate lung barriers for effective pulmonary fibrosis therapy. Nano Today. 2025. https:\/\/doi.org\/10.1016\/j.nantod.2025.102778.","journal-title":"Nano Today"},{"key":"4228_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2022.103712","author":"V Puri","year":"2022","unstructured":"Puri V, Kaur VP, Singh A, Singh C. Recent advances on drug delivery applications of mucopenetrative\/mucoadhesive particles: a review. J Drug Deliv Sci Technol. 2022. https:\/\/doi.org\/10.1016\/j.jddst.2022.103712.","journal-title":"J Drug Deliv Sci Technol"},{"key":"4228_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd9149","author":"CC Wang","year":"2021","unstructured":"Wang CC, Prather KA, Sznitman J, Jimenez JL, Lakdawala SS, Tufekci Z, et al. Airborne transmission of respiratory viruses. Science. 2021. https:\/\/doi.org\/10.1126\/science.abd9149.","journal-title":"Science"},{"key":"4228_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.123004","volume":"316","author":"Y Jeong","year":"2025","unstructured":"Jeong Y, Shim YS, Jo YK, Cha HJ. Redox-activatable inhalable mucoadhesive proteinic nanotherapeutics for targeted treatment of lung cancer. Biomaterials. 2025;316:123004. https:\/\/doi.org\/10.1016\/j.biomaterials.2024.123004.","journal-title":"Biomaterials"},{"key":"4228_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.115111","volume":"202","author":"Z Jin","year":"2023","unstructured":"Jin Z, Gao Q, Wu K, Ouyang J, Guo W, Liang XJ. Harnessing inhaled nanoparticles to overcome the pulmonary barrier for respiratory disease therapy. Adv Drug Deliv Rev. 2023;202:115111. https:\/\/doi.org\/10.1016\/j.addr.2023.115111.","journal-title":"Adv Drug Deliv Rev"},{"key":"4228_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114309","volume":"185","author":"W Wang","year":"2022","unstructured":"Wang W, Huang Z, Huang Y, Zhang X, Huang J, Cui Y, et al. Pulmonary delivery nanomedicines towards circumventing physiological barriers: strategies and characterization approaches. Adv Drug Deliv Rev. 2022;185:114309. https:\/\/doi.org\/10.1016\/j.addr.2022.114309.","journal-title":"Adv Drug Deliv Rev"},{"key":"4228_CR35","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.actbio.2022.05.038","volume":"147","author":"Q Liu","year":"2022","unstructured":"Liu Q, Xue J, Zhang X, Chai J, Qin L, Guan J, Zhang X, Mao S. The influence of a biomimetic pulmonary surfactant modification on the in vivo fate of nanoparticles in the lung. Acta Biomater. 2022;147:391\u2013402. https:\/\/doi.org\/10.1016\/j.actbio.2022.05.038.","journal-title":"Acta Biomater"},{"key":"4228_CR36","doi-asserted-by":"publisher","unstructured":"Gunawan M, Putri KSS, Tirella A, Luckanagul JA, Fernig DG, Boonkanokwong V. Conventional and functionalised nanostructured lipid carriers for pulmonary-targeted delivery systems. Biomater Transl. 2025;55:01-44 https:\/\/doi.org\/10.12336\/bmt.25.00055","DOI":"10.12336\/bmt.25.00055"},{"key":"4228_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2023.122404","volume":"303","author":"B Wang","year":"2023","unstructured":"Wang B, Gao Y, Sun L, Xue M, Wang M, Zhang Z, et al. Inhaled pulmonary surfactant biomimetic liposomes for reversing idiopathic pulmonary fibrosis through synergistic therapeutic strategy. Biomaterials. 2023;303:122404. https:\/\/doi.org\/10.1016\/j.biomaterials.2023.122404.","journal-title":"Biomaterials"},{"key":"4228_CR38","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.actbio.2020.12.061","volume":"123","author":"J Li","year":"2021","unstructured":"Li J, Zheng H, Xu EY, Moehwald M, Chen L, Zhang X, et al. Inhalable PLGA microspheres: tunable lung retention and systemic exposure via polyethylene glycol modification. Acta Biomater. 2021;123:325\u2013 334. https:\/\/doi.org\/10.1016\/j.actbio.2020.12.061.","journal-title":"Acta Biomater"},{"issue":"18","key":"4228_CR39","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adv957","volume":"11","author":"Z Chen","year":"2025","unstructured":"Chen Z, Yang J, Zhang Q, Zeng W, Liu Y, Hu W, et al. Inhalable myofibroblast targeting nanoparticles for synergistic treatment of pulmonary fibrosis. Sci Adv. 2025;11(18):eadv9571. https:\/\/doi.org\/10.1126\/sciadv.adv957.","journal-title":"Sci Adv"},{"key":"4228_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.121910","volume":"623","author":"Y Rao","year":"2022","unstructured":"Rao Y, Sun Y, Li P, Xu M, Chen X, Wang Y, et al. Hypoxia-sensitive adjuvant loaded liposomes enhance the antimicrobial activity of azithromycin via phospholipase-triggered releasing for Pseudomonas aeruginosa biofilms eradication. Int J Pharm. 2022;623:121910. https:\/\/doi.org\/10.1016\/j.ijpharm.2022.121910.","journal-title":"Int J Pharm"},{"issue":"51","key":"4228_CR41","doi-asserted-by":"publisher","first-page":"56498","DOI":"10.1021\/acsami.2c15204","volume":"14","author":"U Chintapula","year":"2022","unstructured":"Chintapula U, Yang S, Nguyen T, Li Y, Jaworski J, Dong H, et al. Supramolecular peptide nanofiber\/PLGA nanocomposites for enhancing pulmonary drug delivery. ACS Appl Mater Interfaces. 2022;14(51):56498\u201356509. https:\/\/doi.org\/10.1021\/acsami.2c15204.","journal-title":"ACS Appl Mater Interfaces"},{"key":"4228_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12989-014-0063-3","volume":"11","author":"M Savi","year":"2014","unstructured":"Savi M, Rossi S, Bocchi L, Gennaccaro L, Cacciani F, Perotti A, et al. Titanium dioxide nanoparticles promote arrhythmias via a direct interaction with rat cardiac tissue. Part Fibre Toxicol. 2014;11:63. https:\/\/doi.org\/10.1186\/s12989-014-0063-3.","journal-title":"Part Fibre Toxicol"},{"key":"4228_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.691227","volume":"12","author":"FM Carlier","year":"2021","unstructured":"Carlier FM, de Fays C, Pilette C. Epithelial barrier dysfunction in chronic respiratory diseases. Front Physiol. 2021;12:691227. https:\/\/doi.org\/10.3389\/fphys.2021.691227.","journal-title":"Front Physiol"},{"issue":"3","key":"4228_CR44","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1164\/rccm.200810-1615OC","volume":"181","author":"TH Sisson","year":"2010","unstructured":"Sisson TH, Mendez M, Choi K, Subbotina N, Courey A, Cunningham A, Dave A, Engelhardt JF, Liu X, White ES, Thannickal VJ, Moore BB, Christensen PJ, Simon RH. Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis. Am J Respir Crit Care Med. 2010;181(3):254\u2013263. https:\/\/doi.org\/10.1164\/rccm.200810-1615OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"4228_CR45","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.actbio.2024.02.008","volume":"177","author":"M Nizamoglu","year":"2024","unstructured":"Nizamoglu M, Alleblas F, Koster T, Borghuis T, Vonk JM, Thomas MJ, White ES, Watson CK, Timens W, El Kasmi KC, Melgert BN, Heijink IH, Burgess JK. Three dimensional fibrotic extracellular matrix directs microenvironment fiber remodeling by fibroblasts. Acta Biomater. 2024;177:118\u2013131. https:\/\/doi.org\/10.1016\/j.actbio.2024.02.008.","journal-title":"Acta Biomater"},{"issue":"9","key":"4228_CR46","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/s41590-023-01551-9","volume":"24","author":"M Bhattacharya","year":"2023","unstructured":"Bhattacharya M, Ramachandran P. Immunology of human fibrosis. Nat Immunol. 2023;24(9):1423\u201333. https:\/\/doi.org\/10.1038\/s41590-023-01551-9.","journal-title":"Nat Immunol"},{"key":"4228_CR47","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00407-2023","author":"T Yanagihara","year":"2023","unstructured":"Yanagihara T, Guignabert C, Kolb MRJ. Endothelial cells in pulmonary fibrosis: more than a bystander. Eur Respir J. 2023. https:\/\/doi.org\/10.1183\/13993003.00407-2023.","journal-title":"Eur Respir J"},{"issue":"16","key":"4228_CR48","doi-asserted-by":"publisher","first-page":"E2048","DOI":"10.1073\/pnas.1415111112","volume":"112","author":"G Oruqaj","year":"2015","unstructured":"Oruqaj G, Karnati S, Vijayan V, Kotarkonda LK, Boateng E, Zhang W, Ruppert C, Gunther A, Shi W, Baumgart-Vogt E. Compromised peroxisomes in idiopathic pulmonary fibrosis, a vicious cycle inducing a higher fibrotic response via TGF-beta signaling. Proc Natl Acad Sci U S A. 2015;112(16):E2048\u20132057. https:\/\/doi.org\/10.1073\/pnas.1415111112.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"30","key":"4228_CR49","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202300545","volume":"19","author":"D Li","year":"2023","unstructured":"Li D, Zhao A, Zhu J, Wang C, Shen J, Zheng Z, et al. Inhaled lipid nanoparticles alleviate established pulmonary fibrosis. Small. 2023;19(30):e2300545. https:\/\/doi.org\/10.1002\/smll.202300545.","journal-title":"Small"},{"issue":"23","key":"4228_CR50","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202315128","volume":"34","author":"M-Y Yang","year":"2024","unstructured":"Yang M-Y, Han M-M, Tang L, Bi Y-Y, Li X-N, Jeong J-H, et al. Dual barrier-penetrating inhaled nanoparticles for enhanced idiopathic pulmonary fibrosis therapy. Adv Funct Mater. 2024;34(23):2315128. https:\/\/doi.org\/10.1002\/adfm.202315128.","journal-title":"Adv Funct Mater"},{"key":"4228_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.cej.2025.167849","volume":"522","author":"D Li","year":"2025","unstructured":"Li D, Tong B, Ouyang S, Chen Y, Wang J, Ding B, et al. Hydrogel-transformable sucralfate microspheres restored gut epithelial wound and reshaped microbiota in colitis via autophagy. Chem Eng J. 2025;522:167849.https:\/\/doi.org\/10.1016\/j.cej.2025.167849","journal-title":"Chem Eng J"},{"issue":"7","key":"4228_CR52","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/s41563-023-01475-7","volume":"22","author":"X Mei","year":"2023","unstructured":"Mei X, Li J, Wang Z, Zhu D, Huang K, Hu S, Popowski KD, Cheng K. An inhaled bioadhesive hydrogel to shield non-human primates from SARS-CoV-2 infection. Nat Mater. 2023;22(7):903\u2013912. https:\/\/doi.org\/10.1038\/s41563-023-01475-7.","journal-title":"Nat Mater"},{"key":"4228_CR53","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202315128","author":"MY Yang","year":"2024","unstructured":"Yang MY, Han MM, Tang L, Bi YY, Li XN, Jeong JH, et al. Dual barrier-penetrating inhaled nanoparticles for enhanced idiopathic pulmonary fibrosis therapy. Adv Funct Mater. 2024. https:\/\/doi.org\/10.1002\/adfm.202315128.","journal-title":"Adv Funct Mater"},{"key":"4228_CR54","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202510848","author":"F Pan","year":"2025","unstructured":"Pan F, Guo ZY, Li BP, Zhang Q, Liu NH, Wu ZQ, et al. Inhalable lipid nanoparticles with mucus clearance and ROS scavenging properties for acute lung injury treatment. Adv Funct Mater. 2025. https:\/\/doi.org\/10.1002\/adfm.202510848.","journal-title":"Adv Funct Mater"},{"key":"4228_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.114038","author":"M Kubczak","year":"2021","unstructured":"Kubczak M, Michlewska S, Bryszewska M, Aigner A, Ionov M. Nanoparticles for local delivery of siRNA in lung therapy. Adv Drug Deliv Rev. 2021. https:\/\/doi.org\/10.1016\/j.addr.2021.114038.","journal-title":"Adv Drug Deliv Rev"},{"key":"4228_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114173","author":"V Forest","year":"2022","unstructured":"Forest V, Pourchez J. Nano-delivery to the lung- by inhalation or other routes and why nano when micro is largely sufficient? Adv Drug Deliv Rev. 2022. https:\/\/doi.org\/10.1016\/j.addr.2022.114173.","journal-title":"Adv Drug Deliv Rev"},{"issue":"8","key":"4228_CR57","doi-asserted-by":"publisher","first-page":"7404","DOI":"10.1007\/s12274-024-6683-5","volume":"17","author":"XY Ji","year":"2024","unstructured":"Ji XY, Chu BB, Wu XF, Xia ZM, Jiang AR, Wang CY, Chen ZM, Zhong DN, Wei QL, Song B, Li WL, Zhong YL, Wang HY, Dong FL, Zhou M, He Y. Naked-eye visualization of lymph nodes using fluorescence nanoprobes in non-human primate-animal models. Nano Res. 2024;17(8):7404\u201314. https:\/\/doi.org\/10.1007\/s12274-024-6683-5.","journal-title":"Nano Res"},{"key":"4228_CR58","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.bioactmat.2023.11.005","volume":"33","author":"WT Lee","year":"2024","unstructured":"Lee WT, Lee H, Kim J, Jung Y, Choi E, Jeong JH, Jeong JH, Lee JH, Youn YS. Alveolar macrophage phagocytosis-evading inhaled microgels incorporating nintedanib-PLGA nanoparticles and pirfenidone-liposomes for improved treatment of pulmonary fibrosis. Bioact Mater. 2024;33:262\u2013278. https:\/\/doi.org\/10.1016\/j.bioactmat.2023.11.005.","journal-title":"Bioact Mater"},{"issue":"2","key":"4228_CR59","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1021\/acsnano.4c15130","volume":"19","author":"S Dong","year":"2025","unstructured":"Dong S, Fang H, Zhu J, Wu Z, Liu Y, Zhu J, et al. Inhalable siRNA targeting IL-11 nanoparticles significantly inhibit bleomycin-induced pulmonary fibrosis. ACS Nano. 2025;19(2):2742\u20132758. https:\/\/doi.org\/10.1021\/acsnano.4c15130.","journal-title":"ACS Nano"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-026-04228-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04228-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04228-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:08:04Z","timestamp":1781651284000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12951-026-04228-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4228"],"URL":"https:\/\/doi.org\/10.1186\/s12951-026-04228-1","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"15 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"576"}}